We have produced a large library of nucleoside and nucleotide analogs prodrugs that specifically target viral RNA polymerases. Based on extensive knowledge and years of experience discovering and developing antivirals, our team of scientists has designed product candidates that include specific chemical modifications intended to enhance antiviral activity and maximize selectivity.
Unique prodrugs of nucleotide analogs are intrinsic to Atea’s innovative platform for developing orally administered, direct-acting antiviral therapies.
AT-527 is an example of the uniqueness of our platform in discovering highly innovative oral nucleotide therapeutics. This sophisticated double prodrug is synthesized as a specific salt form, which required new breakthroughs in our knowledge of medicinal chemistry and cellular pharmacology.